ProfileGDS5678 / 1418238_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 82% 83% 88% 86% 80% 83% 89% 90% 88% 82% 86% 82% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.8434482
GSM967853U87-EV human glioblastoma xenograft - Control 26.0028482
GSM967854U87-EV human glioblastoma xenograft - Control 36.1154483
GSM967855U87-EV human glioblastoma xenograft - Control 47.0172488
GSM967856U87-EV human glioblastoma xenograft - Control 56.6329486
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.5292580
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9266383
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.9749189
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.2666390
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.9581188
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9942982
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.5171386
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.9122582
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2320384